PDSS2

Across TCGA pan-cancer cohorts, PDSS2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PDSS2 data layer compared with 25 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in testicular germ cell tumors (TGCT), where higher PDSS2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PDSS2 expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

TGCT, CESC, and SARC are the cancer types where PDSS2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
TGCT	DFS	Median	All	0.151	0.801	.026	6	view →
CESC	OS	Median	II,III,IV	0.227	0.759	.029	6	view →
SARC	DFS	Median	All	0.121	0.591	.042	3	view →
STAD	DFS	Median	IV	1.000	0.284	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PDSS2–TGCT (DFS)

Open the TGCT breakdown →